Basilea joins INCATE to support antifungal innovation
Allschwil, Switzerland, January 13, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs...
DNA
Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection
– Collaboration is designed to improve analytical speed and accuracy of Freenome's blood-based cancer screening tests – BRISBANE, Calif., Jan. 12, 2026...
Basecamp Research launches world-first AI models for programmable gene insertion
The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of curative cell...
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire /...
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib...
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds...
Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors
Financing led by institutional investors, with participation from new investor Eli Lilly and CompanyInclusive of this investment, a total of...
BillionToOne Provides Guidance for 2026
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a...
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued...
Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access expands through telehealth — here...
Bionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced Therapies
HOUSTON, Jan. 8, 2026 /PRNewswire/ -- Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing...
Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award
Tony Hunter, Ph.D., celebrated for pioneering discoveries that inspired the development of more than 80 cancer therapies that continue to...
Factorial Biotechnologies and Honeycomb Biotechnologies Partner to Deliver High-Throughput, Instrument-Free Single-Cell DNA Sequencing
New partnership combines Factorial's in-cell library preparation chemistry with Honeycomb's HIVE™ platform to enable scalable single-cell WGS workflow with processing...
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy...
Illumina and PREMIA partner to expand clinical access to CGP in Asia
TAIPEI, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a...
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D.,...
Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors...
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in...
4DMT Provides Company Update and Anticipated Development Milestones for 2026
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in...
Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, United Kingdom and NEW YORK, January 7, 2026 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing...